# US 2024/0197690 A1 · Analgesic and antipruritic pharmacertical composition and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197690 A1
- Document ID: US20240197690A1
- Status: Published application
- Kind: A1
- Application number: 18/590,910
- Filed: 2024-02-28
- Published: 2024-06-20
- Earliest claimed: 2020-08-20
- Assignees: Shanghai Ruihukang Pharmaceutical Partnership (Limited Partnership)
- Applicants: Shanghai Ruihukang Pharmaceutical Partnership (Limited Partnership)
- Inventors: Changgeng PENG; Liting SUN; Ruilong XIA
- Web page: https://patentgrep.com/patent/US20240197690A1

## CPC

- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/4164: 1,3-Diazoles
- A61K 31/417: Imidazole-alkylamines, e.g. histamine, phentolamine
- A61K 47/02: Inorganic compounds
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 17/04: Antipruritics
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An analgesic and antipruritic pharmaceutical composition, including PF-05089771 shown as and PF-04885614 shown as An application of the analgesic and antipruritic pharmaceutical composition in the treatment of a disease in which both a voltage-gated sodium channel 1.7 (Nav1.7) and a voltage-gated sodium channel 1.8 (Nav1.8) are involved.

## Claims

### Claim 1

An analgesic and antipruritic pharmaceutical composition, comprising:
PF-05089771, which is
or a salt thereof; and
PF-04885614, which is
or a salt thereof.

### Claim 2 (depends on 1)

The analgesic and antipruritic pharmaceutical composition of claim 1, wherein a weight ratio of the PF-05089771 to the PF-04885614 is (100-1):(1-100).

### Claim 3 (depends on 1)

The analgesic and antipruritic pharmaceutical composition of claim 1, wherein a weight ratio of the PF-05089771 to the PF-04885614 is (50-1):1.

### Claim 4 (depends on 1)

The analgesic and antipruritic pharmaceutical composition of claim 1, wherein a weight ratio of the PF-05089771 to the PF-04885614 is (20-30):1.

### Claim 5 (depends on 1)

The analgesic and antipruritic pharmaceutical composition of claim 1, further comprising:
a pharmaceutically-acceptable carrier;
wherein the pharmaceutically-acceptable carrier is a solvent, an excipient, a dispersion medium, a coating, an iso-osmotic solution, a slow-release agent, or a combination thereof.

### Claim 6 (depends on 5)

The analgesic and antipruritic pharmaceutical composition of claim 5, wherein the pharmaceutically-acceptable carrier is selected from the group consisting of starch, microcrystalline cellulose, lactose, sucrose, mannitol, inorganic salt, hydroxypropyl cellulose, sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, sodium alginate, agar, hydroxypropyl methyl cellulose, methylcellulose, hydroxyethyl cellulose, carbopol, polyvinyl alcohol, acrylic resin, chitosan, beeswax, stearic acid, and a combination thereof.

### Claim 7 (depends on 6)

The analgesic and antipruritic pharmaceutical composition of claim 6, wherein the inorganic salt is selected from the group consisting of calcium sulfate, calcium hydrogen phosphate, calcium carbonate, calcium sulphate dihydrate, and a combination thereof.

### Claim 8 (depends on 1)

The analgesic and antipruritic pharmaceutical composition of claim 1, wherein the analgesic and antipruritic pharmaceutical composition is for treatment of diseases which comprise pruritus and pain; wherein
the pain is inflammatory pain, neuropathic pain or a combination thereof;
the inflammatory pain is selected from the group consisting of postoperative and traumatic pain, musculoskeletal pain, menalgia, visceralgia and a combination thereof;
the musculoskeletal pain comprises arthralgia; and
the neuropathic pain is selected from the group consisting of hemicrania, odontalgia, trigeminal neuralgia, postherpetic pain, pain after spinal cord injury, sciatica, cancer-related pain, diabetic peripheral neuropathy pain, and a combination thereof.

### Claim 9 (depends on 1)

The analgesic and antipruritic pharmaceutical composition of claim 1, wherein an administration route of the analgesic and antipruritic pharmaceutical composition comprises oral administration, intraoral administration, injection, respiratory administration, cutaneous administration, ophthalmic administration, nasal mucosal administration, rectal administration, vaginal administration, otic administration, or dialysis.

### Claim 10

A pharmaceutical composition, comprising:
PF-05089771, which is
or a salt thereof; and
PF-04885614, which is
or a salt thereof;
wherein the pharmaceutical composition is for treatment of diseases in which both a voltage-gated sodium channel 1.7 (Nav1.7) and a voltage-gated sodium channel 1.8 (Nav1.8) are involved.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10, wherein a weight ratio of the PF-05089771 to the PF-04885614 is (100-1):(1-100).

### Claim 12 (depends on 10)

The pharmaceutical composition of claim 10, wherein a weight ratio of the PF-05089771 to the PF-04885614 is (50-1):1.

### Claim 13 (depends on 10)

The pharmaceutical composition of claim 10, wherein a weight ratio of the PF-05089771 to the PF-04885614 is (20-30):1.

### Claim 14 (depends on 10)

The pharmaceutical composition of claim 10, further comprising:
a pharmaceutically-acceptable carrier;
wherein the pharmaceutically-acceptable carrier is a solvent, an excipient, a dispersion medium, a coating, an iso-osmotic solution, a slow-release agent, or a combination thereof.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14, wherein the pharmaceutically-acceptable carrier is selected from the group consisting of starch, microcrystalline cellulose, lactose, sucrose, mannitol, inorganic salt, hydroxypropyl cellulose, sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, sodium alginate, agar, hydroxypropyl methyl cellulose, methylcellulose, hydroxyethyl cellulose, carbopol, polyvinyl alcohol, acrylic resin, chitosan, beeswax, stearic acid, and a combination thereof.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15, wherein the inorganic salt is selected from the group consisting of calcium sulfate, calcium hydrogen phosphate, calcium carbonate, calcium sulphate dihydrate, and a combination thereof.

### Claim 17 (depends on 10)

The pharmaceutical composition of claim 10, wherein the diseases comprise pruritus and pain; wherein
the pain is inflammatory pain, neuropathic pain or a combination thereof;
the inflammatory pain is selected from the group consisting of postoperative and traumatic pain, musculoskeletal pain, menalgia, visceralgia and a combination thereof;
the musculoskeletal pain comprises arthralgia; and
the neuropathic pain is selected from the group consisting of hemicrania, odontalgia, trigeminal neuralgia, postherpetic pain, pain after spinal cord injury, sciatica, cancer-related pain, diabetic peripheral neuropathy pain, and a combination thereof.

### Claim 18 (depends on 10)

The pharmaceutical composition of claim 10, wherein an administration route of the pharmaceutical composition comprises oral administration, intraoral administration, injection, respiratory administration, cutaneous administration, ophthalmic administration, nasal mucosal administration, rectal administration, vaginal administration, otic administration, or dialysis.

### Claim 19

A method of treating a disease involving pain or itching, comprising administering to a subject in need a pharmaceutical composition, wherein the pharmaceutical composition comprises:
PF-05089771, which is
or a salt thereof; and
PF-04885614, which is
or a salt thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein an administration route of the pharmaceutical composition comprises oral administration, intraoral administration, injection, respiratory administration, cutaneous administration, ophthalmic administration, nasal mucosal administration, rectal administration, vaginal administration, otic administration, or dialysis.
